### UpToDate臨床決策輔助工具

Ginger瀞文 Customer Success Specialist 客戶關係顧問 Mar 2022



## **Dr. Bud Rose**

- ✓ 腎臟科醫師、老師
   ✓ 臨床時遇到的2/3問題無法解答
- ✓ 他為自己編寫的教科書總是很快過時而感到 苦惱,可用電腦搜尋、立即更新(電子化)
- ✔ 臨床決策輔助工具
- ✓ UpToDate主要是告訴醫生怎樣治療患有這種疾病的病人,並不是取代教科書
- ✓ 主要用於解決教科書....不能解決的問題

sk any doctor, nurse, or other clinician about <u>UpToDate</u> and you'll get some version of this answer: I use it all the time to stay current, and often pull it up when I'm talking with patients. For clinicians around the world, UpToDate is essentially Google for medicine, but smarter and based on evidence.

醫學界的

google

# What is UpToDate?

Evidence base clinical decision Support tool to help clinicians :

- Answer clinical questions
- Improve clinical knowledge
- Enhance patient outcomes



### UpToDate (Feb 2021)

- 25 Specialties
- 12,000+ Clinical topics
- 1,500+ Patient topics
- 7,300+ Physician Authors
- 6,900+ Drug entries
- 38,000+ Graphics
- 514,000 References
- 200+ Calculators



### **Radiation dermatitis**

Authors: Julie Ryan Wolf, PhD, MPH, Angela M Hong, MBBS, MMed, PhD, FRANZCR Section Editors: Joseph Fowler, MD, David E Wazer, MD Deputy Editor: Rosamaria Corona, MD, DSc

General Surgery

Hospital Medicine

Geriatrics

Hematology

**Contributor Disclosures** 

All topics are updated as new evidence becomes available and our peer review process is complete.

Back Authors and Editors <

Allergy and Immunology Anesthesiology Calculators Cardiovascular Medicine Dermatology Drug Information Emergency Medicine (Adult and Pediatric) Endocrinology and Diabetes Family Medicine and General Practice Gastroenterology and Hepatology



<ol> <li>Wolters</li> </ol>	Kluwer
-----------------------------	--------

網路也搜尋得到 <sup>,</sup> 全球的作者&背景喔!		
Palliative Care		
Patient Education		
Pediatrics		
Primary Care (Adult)		
Primary Care Sports Medicine (Adolescents and Adults)		
Psychiatry		
Pulmonary and Critical Care Medicine		
Rheumatology		
Sleep Medicine		

每個topic最上方,會看到作者群名稱

### UpToDate的國際作者,其中有4位醫師是來自台灣!

#### GRADE for practice guidelines

Grade of recommendation*	Clarity of risk/benefit	Quality of supporting evidence	Implications
1A Strong recommendation High quality evidence	Benefits clearly outweigh risk and burdens, or vice versa	Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.	Strong recommendation, can apply to most patients in most circumstances without reservation
18 Strong recommendation Moderate quality evidence	Benefits dearly outweigh risk and burdens, or vice versa	Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologi faws, indirect or imprecise), or very strong evidence of some other form. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.	Strong recommendation, likely to apply to most patients
1C Strong recommendation Low quality evidence	Benefits appear to outweigh risk and burdens, or vice versa	Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.	Relatively strong recommendation; might change when higher quality evidence becomes available
2A Weak recommendation High quality evidence	Benefits closely balanced with risks and burdens	Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.	Weak recommendation, best action may differ depending on circumstances or patients or societal values
28 Weak recommendation Moderate quality evidence	Benefits dosely balanced with risks and burdens, some uncertainty in the estimates of benefits, risks and burdens	Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other form. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.	Weak recommendation, alternative approaches ikely to be better for some patients under some circumstances
2C Weak recommendation Low quality evidence	Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens	Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.	Very weak recommendation; other alternatives may be equally reasonable

\* GRADE can be implemented with either three or four levels of quality of evidence. UpToDate implements three levels and uses numbers and letters to represent strength of recommendation and quality of evidence respectively.





#### **Grade 2B recommendation**

A Grade 2B recommendation is a weak recommendation; alternative approaches may be better for some patients under some circumstances.

#### **Explanation:**

A Grade 2 recommendation is a weak recommendation. It means "this is our suggestion, but you may want to think about it." It is unlikely that you should follow the suggested approach in all your patients, and you might reasonably choose an alternative approach. For Grade 2 recommendations, benefits and risks may be finely balanced, or the benefits and risks may be uncertain. In deciding whether to follow a Grade 2 recommendation in an individual patient, you may want to think about your patient's risk aversion.

Grade B means that the best estimates of the critical benefits and risks come from randomized, controlled trials with important limitations (eg, inconsistent results, methodologic flaws, imprecise results, extrapolation from a different population or setting) or very strong evidence of some other form. Further research (if performed) is likely to have an impact on our confidence in the estimates of benefit and risk, and may change the estimates.

#### **Recommendation grades**

- 1. Strong recommendation: Benefits clearly outweigh the risks and burdens (or vice versa) for most, if not all, patients
- 2. Weak recommendation: Benefits and risks closely balanced and/or uncertain

#### **Evidence grades**

- A. High-quality evidence: Consistent evidence from randomized trials, or overwhelming evidence of some other form
- B. Moderate-quality evidence: Evidence from randomized trials with important limitations, or 🚽 strong evidence of some other form
- C. Low-quality evidence: Evidence from observational studies, unsystematic clinical observations, or from randomized trials with serious flaws

For a complete description of our grading system, please see the UpToDate editorial policy.

- Modern radiation therapy techniques, such as intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc radiation therapy (VMAT), which deliver radiation to the planned treatment volume while minimizing radiation to normal tissue outside the target, may reduce the occurrence of radiation dermatitis. (See <u>'Prevention'</u> above.)
- For patients undergoing radiation therapy, we suggest prophylactic topical corticosteroids in addition to general skin care measures for the prevention of radiation dermatit s (**Grade 2B**). Jow- to medium-potency topical corticosteroids (groups 4 to 6 (<u>III table 5</u>)) are applied to the treatment field once or twice daily, after each radiotherapy session. Agents of unproven efficacy include aloe vera, <u>trolamine</u>, <u>sucralfate</u>, hyaluronic acid, <u>silver sulfadiazine</u>, and silver nylon dressings. (See <u>'Prevention'</u> above and <u>'Topical corticosteroids'</u> above.)

### 🥑. Wolters Kluwer

### Solutions to Reduce Unwanted Variability in Care

## UpToDate®



Evidence-based clinical decision support for disease and conditions

Pharmacological information and medication decision support

Lexicomp

- Hospital-wide tool
- Design for clinicians

### Together ...

these trusted brands provide the industry's most comprehensive medication and disease solution to support hospital clinicians' decision making and help enhance patient safety



# UpToDate demo













## Easy registration process

Contents v Calculators	Drug Interactions			Register	Log Ir
		Search UpToDate	Click "Register" to be brought to a registration form		





i Wolters Kluwer

## 90 Day Re-Verification

In-application & email messaging reminds clinicians to verify their affiliation with the organization to maintain remote access rights.





### Thank You!

